Had mild-to-moderate psoriasis on my elbows and scalp since about 2020, which my derm chalked up to stress plus post-op inflammation. Tried everything short of biologics. Nothing cleared it fully. Started compounded sema March 2024 at 241 lbs, switched to brand Zepbound 7.5 last August. Around month four or five I noticed the elbow patches were smaller. By month eight they were almost gone. Scalp still flares but way less than before. I did not start this for skin. I started this because I regained 73 lbs after my 2017 bypass and the shame was eating me alive. The psoriasis improvement was completely incidental. My working theory: tirzepatide has meaningful anti-inflammatory effects, and psoriasis is fundamentally an inflammatory disease. Also, I’ve lost 44 lbs since March 2024, and excess adipose tissue drives systemic inflammation on its own. Can’t isolate the variables. Anyone else with a history of inflammatory skin conditions notice this? Especially curious if post-op folks have a different response given the gut-skin axis is probably rewired after bypass.
The adipose-inflammation link you named is real, but I’d be careful about treating it as the primary driver here. The 44 lb loss alone could reduce systemic IL-6 and TNF-alpha enough to meaningfully quiet a psoriatic response, even without any direct GLP-1/GIP receptor mechanism. The “can’t isolate the variables” framing is exactly right, and I’d gently push back on weighting the tirzepatide pharmacology too heavily before you have a data point from someone who maintained the same weight loss through other means and saw the same skin improvement. The post-op gut-skin axis question is the more interesting thread tbh. Bypass changes bile acid signaling and microbiome composition in ways that could interact with the GIP arm of tirz differently than an intact gut. Whether that amplifies or dampens the inflammatory effect, I genuinely don’t know. Would be curious if your derm has any read on the timing correlation.
The “same weight loss through other means” control is exactly what’s missing and I agree that’s the cleanest argument for humility here.
But the timing is nagging at me: my patches started shrinking around month four or five, when my total loss was maybe 18-20 lbs. Not nothing, but also not the kind of number that typically moves the needle on a chronic inflammatory skin condition ime. Could still be the weight. Just wouldn’t call it settled
the 18-20 lb timing point is actually the most useful data in this thread, because it’s the part that strains the pure adipose-reduction explanation. there’s a handful of studies showing GLP-1 agonism directly suppresses TNF-alpha and IL-6 independent of weight change, and psoriasis flare severity correlates with both. it’s not the IL-17/IL-23 axis directly, so it’s not a clean mechanism, but “four months in at modest loss” fits the timeline of direct receptor activity better than it fits systemic inflammation from fat loss alone. can’t rule out confounders, but “can’t call it settled” is probably the right place to land.
“can’t isolate the variables” is the honest part of this post and i’d actually push on the inflammatory mechanism claim being load-bearing here. 44 lbs of adipose loss alone moves hs-CRP and IL-6 meaningfully, and psoriasis severity tracks BMI in the literature pretty consistently, so the weight delta is a sufficient explanation before you even need a direct tirz anti-inflammatory effect. the cleaner test would be someone whose psoriasis improved without significant weight loss on a GLP-1, and i haven’t seen that case reported well. also worth flagging: you switched from compounded sema to brand tirz around the time the elbows cleared, so molecule and formulation both changed. messy timeline for causal claims, fwiw.
the bypass piece is what i’d actually sit with longer here, because RYGB already shifts your incretin physiology, postprandial GLP-1 runs higher after bypass than in unoperated patients, so adding a GLP-1/GIP agonist on top is mechanistically a different intervention than starting one in a non-bypass body. that doesn’t undercut the inflammation theory, it just adds another confound on top of the adipose one you already named. the part i’d push on a bit is the sema-then-tirz switch. you spent five months on a GLP-1 mono before going to dual agonism, and the elbow improvement timeline straddles that switch. if the mechanism were purely “GLP-1 class anti-inflammatory” you’d expect the curve to look different from “GIP added to the picture changed something.” can’t tell which from a single timeline, but it’s worth flagging when the next person reads this and assumes tirz specifically did it. really glad the scalp is calmer too.